01897nas a2200181   4500000000100000008004100001100001400042700001300056700001200069700001400081700001400095245007800109856006800187300001200255490000700267520142700274022001401701       2019                            d1 aSousa EJS1 aSousa GC1 aBaia VF1 aSomensi D1 aXavier MB00aBotulinum toxin type A in chronic neuropathic pain in refractory leprosy.  uhttp://www.scielo.br/pdf/anp/v77n5/1678-4227-anp-77-05-0346.pdf  a346-3510 v773 a<p><strong>OBJECTIVE: </strong>Neuropathic pain is a chronic syndrome that is difficult to treat and often affects patients with leprosy. Recommended treatment includes the the use of analgesic drugs, codeine, tricyclic antidepressants, neuroleptics, anticonvulsants and thalidomide, but without consensus on uniform dose and fully satisfactory results. To analyze botulinum toxin type A (BoNT-A) effectiveness in treatment of chronic neuropathic pain in refractory leprous patients, as well as evaluate and compare the quality of life of patients before and after using the medication.</p>

<p><strong>METHODS: </strong>We used a specific protocol including clinical, demographic, DN4 protocol, analogue scale (VAS), sensory evaluation and evaluation of the WHOQOL-BREF. Therapeutic intervention was performed with BOTOX® BTX-A 100U administered subcutaneously. Fifteen patients were evaluated on days 0, 10 and 60.</p>

<p><strong>RESULTS: </strong>Patients on VAS showed pain between 5 and 10, in one case there was complete pain relief in 60 days, while others showed improvement in the first week with the return of symptoms with less intensity after this period. WHOQOL-BREF's domains Quality of Life and Physical to have a significant increase in QOL.</p>

<p><strong>CONCLUSION: </strong>BoNT-A proved to be a good therapeutic option in relieving pain with improved quality of life for these patients.</p>
  a1678-4227